midazolam and brivanib

midazolam has been researched along with brivanib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clemens, PL; Dhar, A; Kollia, G; Lathers, D; Masson, E; Syed, S; Walters, I	1

Trials

1 trial(s) available for midazolam and brivanib

Article	Year
Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants. Journal of clinical pharmacology, 2012, Volume: 52, Issue:6 Topics: Administration, Oral; Adult; Alanine; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Fibroblast Growth Factors; Half-Life; Humans; Injections, Intravenous; Intestines; Liver; Male; Metabolic Detoxication, Phase I; Midazolam; Middle Aged; Patient Dropouts; Prodrugs; Receptors, Vascular Endothelial Growth Factor; Triazines	2012

Article

Year

Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.

Journal of clinical pharmacology, 2012, Volume: 52, Issue:6

Topics: Administration, Oral; Adult; Alanine; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Fibroblast Growth Factors; Half-Life; Humans; Injections, Intravenous; Intestines; Liver; Male; Metabolic Detoxication, Phase I; Midazolam; Middle Aged; Patient Dropouts; Prodrugs; Receptors, Vascular Endothelial Growth Factor; Triazines

2012